Amphastar P (AMPH)

Currency in USD
30.45
-0.06(-0.18%)
Real-time Data·
AMPH Scorecard
Full Analysis
Management has been aggressively buying back shares
AMPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.1830.55
52 wk Range
20.3953.96
Key Statistics
Prev. Close
30.5
Open
30.53
Day's Range
30.18-30.55
52 wk Range
20.39-53.96
Volume
18.43K
Average Volume (3m)
546.59K
1-Year Change
-36.39%
Book Value / Share
16.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AMPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
32.00
Upside
+5.09%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Amphastar P News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Amphastar P Company Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Employees
2028

Amphastar P Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.85 beat forecast by 14.86%, revenue at $174.4M slightly above expectations; stock rose 3.84% after hours
  • Baqsimi sales grew 21% YoY, offsetting declines in Glucagon and Epinephrine; company maintains guidance for flat sales YoY
  • New $50M stock buyback program announced; management signals confidence in company's value proposition
  • Potential approvals for AMP-002 and AMP-015 in 2025 could boost future performance; executives optimistic about FDA approval
  • Challenges include increased competition, declining glucagon market, and potential regulatory hurdles for new product approvals
Last Updated: 08/08/2025, 12:28
Read Full Transcript

Compare AMPH to Peers and Sector

Metrics to compare
AMPH
Peers
Sector
Relationship
P/E Ratio
10.5x−3.6x−0.6x
PEG Ratio
−0.71−0.110.00
Price/Book
1.9x0.8x2.6x
Price / LTM Sales
2.0x0.9x3.3x
Upside (Analyst Target)
6.6%21.2%37.4%
Fair Value Upside
Unlock40.4%4.5%Unlock

Analyst Ratings

3 Buy
3 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 32.00
(+5.09% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
0.85 / 0.74
Revenue / Forecast
174.40M / 173.95M
EPS Revisions
Last 90 days

AMPH Income Statement

People Also Watch

19.32
SRPT
-4.45%
189.39
IQV
-0.92%
28.85
CNC
-1.90%
85.92
CROX
-0.74%
21.700
CPRX
+2.94%

FAQ

What Stock Exchange Does Amphastar P Trade On?

Amphastar P is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Amphastar P?

The stock symbol for Amphastar P is "AMPH."

What Is the Amphastar P Market Cap?

As of today, Amphastar P market cap is 1.41B.

What Is Amphastar P's Earnings Per Share (TTM)?

The Amphastar P EPS (TTM) is 2.82.

When Is the Next Amphastar P Earnings Date?

Amphastar P will release its next earnings report on 09 Nov 2025.

From a Technical Analysis Perspective, Is AMPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Amphastar P Stock Split?

Amphastar P has split 0 times.

How Many Employees Does Amphastar P Have?

Amphastar P has 2028 employees.

What is the current trading status of Amphastar P (AMPH)?

As of 25 Aug 2025, Amphastar P (AMPH) is trading at a price of 30.45, with a previous close of 30.50. The stock has fluctuated within a day range of 30.18 to 30.55, while its 52-week range spans from 20.39 to 53.96.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.